UNIVERSITY OF WASHINGTON
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Computer Assisted Rx Education for HIV-Positives: CARE+
Not Applicable
Completed
- Conditions
- HIV InfectionsAcquired Immunodeficiency Syndrome
- Interventions
- Behavioral: CARE+
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 240
- Registration Number
- NCT00443378
- Locations
- 🇺🇸
Madison Clinic, Harborview Medical Center, Seattle, Washington, United States
🇺🇸Lifelong AIDS Alliance, Seattle, Washington, United States
Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity
Phase 2
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2011-02-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 36
- Registration Number
- NCT00439972
- Locations
- 🇺🇸
University of Washington, Northwest Lipid Research Clinic, Seattle, Washington, United States
SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentAlzheimer's Disease
- Interventions
- Drug: PlaceboDrug: Regular Insulin
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 173
- Registration Number
- NCT00438568
- Locations
- 🇺🇸
Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Phase 1
Completed
- Conditions
- Stage III Ovarian Epithelial CancerStage IV Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorHER2-positive Breast CancerStage IIIC Breast CancerStage III Ovarian Germ Cell Tumor
- Interventions
- Biological: pNGVL3-hICD vaccineOther: flow cytometryOther: immunologic techniqueOther: immunoenzyme techniqueGenetic: protein expression analysisProcedure: biopsy
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 66
- Registration Number
- NCT00436254
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT00434005
- Locations
- 🇺🇸
Northlake Laboratory, Seattle, Washington, United States
Does Block Play Improve Language Acquisition: A Randomized Trial
Not Applicable
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 200
- Registration Number
- NCT00428376
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
Phase 3
Terminated
- Conditions
- HIV Infections
- Interventions
- Drug: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)Drug: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)Drug: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)Drug: d4T/3TC/ABC (stavudine/lamivudine/abacavir)Drug: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 34
- Registration Number
- NCT00427297
- Locations
- 🇰🇪
Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
Not Applicable
Terminated
- Conditions
- HIV Infections
- Interventions
- Drug: HAART
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 140
- Registration Number
- NCT00428116
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase 1
Completed
- Conditions
- Stage IIIC Breast CancerStage IV Breast CancerMale Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer
- Interventions
- Biological: ONTAKOther: flow cytometryOther: immunohistochemistry staining methodOther: enzyme-linked immunosorbent assayOther: laboratory biomarker analysisGenetic: protein expression analysis
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT00425672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT00425646
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath